Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes-Reference-Cited by-同舟云学术

Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes

Published:2019-11 Issue:11 Volume:5 Page:2969-2986
ISSN:2451-9294
Container-title:Chem
language:en
Short-container-title:Chem

Author:

La Sala Giuseppina,Olieric Natacha,Sharma Ashwani,Viti Federica,de Asis Balaguer Perez Francisco,Huang Lan,Tonra James R.,Lloyd G. Kenneth,Decherchi Sergio,Díaz José Fernando,Steinmetz Michel O.,Cavalli Andrea

Funder

BeyondSpring Pharmaceuticals

Ministerio de Ciencia, Innovación y Universidades

Swiss National Science Foundation

Regione Lombardia

Publisher

Elsevier BV

Subject

Materials Chemistry,Biochemistry (medical),General Chemical Engineering,Environmental Chemistry,Biochemistry,General Chemistry

Reference67 articles.

1. Microtubule-binding agents: a dynamic field of cancer therapeutics;Dumontet;Nat. Rev. Drug Discov.,2010

2. Microtubule-targeting agents: strategies to hijack the cytoskeleton;Steinmetz;Trends Cell Biol.,2018

3. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures;Li;Future Med. Chem.,2017

4. Microtubules and resistance to tubulin-binding agents;Kavallaris;Nat. Rev. Cancer,2010

5. TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines;Tame;Oncotarget,2017

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study;Lung Cancer;2024-09

2. The RNA-binding protein EIF4A3 promotes axon development by direct control of the cytoskeleton;Cell Reports;2024-09

3. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial;The Lancet Respiratory Medicine;2024-09

4. Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors;Expert Opinion on Pharmacotherapy;2024-05-23

5. Design, synthesis, and structure–activity relationship study of novel plinabulin derivatives as anti-tumor agents based on the co-crystal structure;Molecular Diversity;2024-04-23